Structure-Activity Relationship Study of Collagen-Derived Anti-Angiogenic Biomimetic Peptides

Chemical Biology and Drug Design

Volumn 80, Issue 1, 2012, Pages 27-37

  Rosca, Elena V ^a   Koskimaki, Jacob E ^a   Pandey, Niranjan B ^a   Tamiz, Amir P ^a   Popel, Aleksander S ^a,b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Age related macular degeneration; Angiogenesis; Cancer; Endothelial cell; Lymphangiogenesis; Peptidomimetics

Indexed keywords

ANGIOGENESIS INHIBITOR; COLLAGEN TYPE 4; DEXTRO ALANINE; ISOLEUCINE; METHIONINE; PEPTIDOMIMETIC AGENT; SP 2009 PEPTIDE; SP 2010 PEPTIDE; SP 2011 PEPTIDE; SP 2012 PEPTIDE; SP 2020 PEPTIDE; SP 2021 PEPTIDE; SP 2022 PEPTIDE; SP 2023 PEPTIDE; SP 2024 PEPTIDE; SP 2025 PEPTIDE; SP 2030 PEPTIDE; SP 2031 PEPTIDE; SP2004 PEPTIDE; SP2006 PEPTIDE; SP2007 PEPTIDE; SP2008 PEPTIDE; SP2012 PEPTIDE; SP2013 PEPTIDE; SP2014 PEPTIDE; SP2028 PEPTIDE; SP2029 PEPTIDE; SP2032 PEPTIDE; SP2033 PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LYMPHATIC ENDOTHELIAL CELL; MICROTUBULE; MICROVASCULAR ENDOTHELIAL CELL; NEOPLASM; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; RETINA MACULA AGE RELATED DEGENERATION; STRUCTURE ACTIVITY RELATION; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINO ACID SEQUENCE; ANGIOGENIC PROTEINS; BIOMIMETIC MATERIALS; CELL MOVEMENT; COLLAGEN TYPE V; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MOLECULAR SEQUENCE DATA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862137831     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01376.x     Document Type: Article

References (26)

1. Saladin P.M., Zhang B.D., Reichert J.M. (2009) Current trends in the clinical development of peptide therapeutics. IDrugs;12:779-784.
2. Nabors L.B., Fiveash J.B., Markert J.M., Kekan M.S., Gillespie G.Y., Huang Z., Johnson M.J., Meleth S., Kuo H, Gladson C.L., Fathallah-Shaykh H.M. (2010) A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol;67:313-319.
3. Bradley D.A., Daignault S., Ryan C.J., Dipaola R.S., Smith D.C., Small E. et al. (2010) Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs;29:1432-1440.
4. Reardon D.A., Fink K.L., Mikkelsen T., Cloughesy T.F., O'Neill A., Plotkin S. et al. (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol;26:5610-5617.
5. Kenny L.M., Coombes R.C., Oulie I., Contractor K.B., Miller M., Spinks T.J. et al. (2008) Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med;49:879-886.
6. Rosca E.V., Koskimaki J.E., Pandey N.B., Rivera C.G., Tamiz A.P., Popel A.S. (2011) Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol;12:1101-1116.
7. Bhutia S.K., Maiti T.K. (2008) Targeting tumors with peptides from natural sources. Trends Biotechnol;26:210-217.
8. Pernot M., Vanderesse R., Frochot C., Guillemin F., Barberi-Heyob M. (2011) Stability of peptides and therapeutic success in cancer. Expert Opin Drug Metab Toxicol;7:793-802.
9. Gentilucci L., De Marco R., Cerisoli L. (2010) Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des;16:3185-3203.
10. Abraham S., Guo F., Li L.S., Rader C., Liu C., Barbas C.F. III et al. (2007) Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation. Proc Natl Acad Sci U S A;104:5584-5589.
11. Hruby V.J., Sharma S.D., Toth K., Jaw J.Y., al-Obeidi F., Sawyer T.K. et al. (1993) Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann N Y Acad Sci;680:51-63.
12. Li M., Oliver E., Kitchens K.M., Vere J., Alkan S.S., Tamiz A.P. (2008) Structure-activity relationship studies of permeability modulating peptide AT-1002. Bioorg Med Chem Lett;18:4584-4586.
13. Gautier B., Goncalves V., Diana D., Di Stasi R., Teillet F., Lenoir C. et al. (2010) Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem;53:4428-4440.
14. Mirochnik Y., Aurora A., Schulze-Hoepfner F.T., Deabes A., Shifrin V., Beckmann R. et al. (2009) Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res;15:1655-1663.
15. Haviv F., Bradley M.F., Kalvin D.M., Schneider A.J., Davidson D.J., Majest S.M. et al. (2005) Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem;48:2838-2846.
16. Folkman J. (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med;285:1182-1186.
17. Folkman J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol;29:15-18.
18. Karagiannis E.D., Popel A.S. (2008) A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci USA;105:13775-13780.
19. Karagiannis E.D., Popel A.S. (2007) Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties. Biochem Biophys Res Commun;354:434-439.
20. Koskimaki J.E., Karagiannis E.D., Rosca E.V., Vesuna F., Winnard P.T. Jr, Raman V. et al. (2009) Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia;11:1285-1291.
21. Koskimaki J.E., Karagiannis E.D., Tang B.C., Hammers H., Watkins D.N., Pili R. et al. (2010) Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer;10:29.
22. Rosca E.V., Koskimaki J.E., Pandey N.B., Wolff A.C., Popel A.S. (2011) Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biol Ther;12:808-817.
23. Arnaoutova I., George J., Kleinman H.K., Benton G. (2009) The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis;12:267-274.
24. Eikesdal H.P., Sugimoto H., Birrane G., Maeshima Y., Cooke V.G., Kieran M. et al. (2008) Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc Natl Acad Sci U S A;105:15040-15045.
25. Rivera C.G., Rosca E.V., Pandey N.B., Koskimaki J.E., Bader J.S., Popel A.S. (2011) Novel peptide-specific QSAR analysis applied to collagen IV peptides with antiangiogenic activity. J Med Chem;54:6492-6500.
26. Lee E., Rosca E.V., Pandey N.B., Popel A.S. (2011) Small peptides derived from somatotropin conserved domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Int J Biochem Cell Biol;43:1812-1821.